

# Terazon<sup>®</sup>

Terazosin 2 & 5 mg tablet



## Presentation

Terazon<sup>®</sup>2: Each tablet contains Terazosin hydrochloride INN equivalent to Terazosin 2 mg.

Terazon<sup>®</sup>5: Each tablet contains Terazosin hydrochloride INN equivalent to Terazosin 5 mg.

## Description

Terazon (Terazosin hydrochloride) is a selective alpha-1 adrenoreceptor competitive blocking agent with a longer duration of action. Terazosin is a quinazoline derivative. It is very rapidly absorbed and performed activity within 15 minutes after oral ingestion.

## Indication

\* Single therapy is used to relieve for signs and symptoms of benign prostatic hyperplasia (BPH)

\* For the treatment of hypertension

## Dosage regimen

Benign Prostatic Hyperplasia

*Initial dose:* 1 mg at bedtime is starting dose of all patients and this dose should not be exceeded.

*Subsequent dose:* The dose slowly increases to achieve the desired response. The usual recommended dose range is 5-10 mg administered once a day.

Hypertension

*Initial dose:* 1 mg at bedtime is starting dose of all patients and this dose should not be exceeded.

*Subsequent dose:* The dose slowly increases to achieve the desired response. The usual recommended dose range is 2-10 mg administered once a day.

## Contraindication

Terazosin is contraindicated in patients known to be hypersensitive to Terazosin or its analogues.

## Precautions

First dose may cause hypotension (within 30-90 minutes). Therefore should be taken on retiring to bed.

Caution should be observed when Terazosin is administered with other antihypertensive agents, avoid the possibility of significant hypotension. When adding Terazosin to a diuretic or other antihypertensive agent, dosage reduction and retitration may be necessary.

The patients should be cautioned to avoid situation such as driving and hazardous tasks where injury could result due to syncope after initiation of Terazosin therapy.

## Side effects

Postural hypertension is more commonly reported side effect. Dizziness, lack of energy, peripheral oedema; urinary frequency and priapism reported.

## Use in Pregnancy and Lactation

The safety of Terazosin during pregnancy has not been established so Terazosin is not recommended during pregnancy unless the potential benefit justifies the potential risk to mother and fetus. It is not known whether Terazosin is excreted in breast milk. Because many drugs are excreted in breast milk, caution should be exercised when Terazosin is administered to a nursing mother.

## Overdose

Acute overdose may lead to acute hypotension, cardiovascular support is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in a supine position. At the same time expansion of plasma volume and nor-adrenergic vasopressor may also be needed.

## Drug Interaction

\*In patients receiving Terazosin plus ACE inhibitors or diuretics the proportion reporting dizziness or related side effects was greater than in the total population of Terazosin treated patients from clinical trials.

\*Terazosin has been given without interaction with analgesics/anti-inflammatory, cardiac glycosides, hypoglycemic, antiarrhythmic, anxiolytics/sedatives, antibacterial, hormones/steroids and drugs used for gout.

## Storage

Do not store above 30°C. Keep away from light and out of the reach of children.

## Commercial pack

Terazon<sup>®</sup>2: Box containing 5 blister strips of 10 tablets

Terazon<sup>®</sup>5: Box containing 3 blister strips of 10 tablets

